<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578564</url>
  </required_header>
  <id_info>
    <org_study_id>SOR-C13 01</org_study_id>
    <nct_id>NCT01578564</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel</brief_title>
  <official_title>Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soricimed Biopharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soricimed Biopharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of the drug SOR-C13
      when given as an intravenous infusion in patients with ovarian cancer or other cancers known
      to over express the TRPV6 calcium channel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Over 21 days from initial administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of SOR-C13</measure>
    <time_frame>Pre-treatment and up to 4 hours post-treatment on Study Days 1, 3, 8 and 10</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>SOR-C13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOR-C13</intervention_name>
    <description>Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period</description>
    <arm_group_label>SOR-C13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Males and females ≥ 18 years of age

          -  Subjects with a histologic diagnosis of solid tumor cancers of epithelial origin.

          -  Subjects with advanced refractory cancer for which standard curative or palliative
             measures do not exist or are no longer effective. There is no limitation on the number
             or types of prior therapy.

          -  Subjects must have recovered from major infections and/or surgical procedures and, in
             the opinion of the investigator, not have a significant active concurrent medical
             illness precluding protocol treatment.

          -  ECOG (Eastern Cooperative Oncology Group) Performance Score ≤ 1.

          -  Life expectancy of greater than 12 weeks.

          -  Subjects must have adequate organ and marrow function as defined below:

               1. hemoglobin ≥9.0 g/dL (≥5.6 mmol/L)

               2. white blood cells ≥3,000/mm³(≥3×10⁹/L)

               3. absolute neutrophil count ≥1,500/mm³ (≥1.5×10⁹/L)

               4. platelets ≥100,000/μL (≥100×10⁹/L)

               5. total bilirubin ≤1.5× upper limit of normal(ULN)

               6. AST/ALT/AP ≤2.5× ULN (ALT/AST ≤5.0x ULN in case of documented liver metastases

               7. creatinine ≤1.5× ULN

               8. albumin ≥3.0 g/dL (≥30 g/L)

               9. INR ≤1.4

          -  Ability to understand and voluntarily sign the informed consent document

        Exclusion Criteria:

          -  Chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy
             will not be allowed within either 30 days, or 5 half lives (whichever is longer) prior
             to study drug administration.

          -  History or clinical evidence of central nervous system (CNS) tumor involvement
             (metastases) or other known clinically relevant CNS pathology (e.g., epilepsy,
             seizure, paresis, aphasia, cerebellar disease, severe brain injury, psychosis).

          -  Concurrent malignancy other than the solid tumor under investigation, requiring active
             treatment.

          -  History of clinically significant allergic reaction attributed to any injected
             compound.

          -  History of any of the following cardiovascular events or conditions within the past 6
             months prior to enrolment: myocardial infarction, unstable angina, cerebrovascular
             accident or transient ischemic attack, New York Heart Association Class ≥ II chronic
             heart failure, hypokalemia, significant arrhythmia*; QTc interval &gt;430 msec or use of
             drugs that prolong the QT interval at screening; family history of long QT syndrome.(*
             Significant arrhythmias are defined as symptoms of syncope or severe palpitations
             (palpitations requiring referral to cardiac monitoring), or ECG findings of
             supraventricular tachycardia (including ventricular fibrillation) or ventricular
             ectopy (ventricular premature depolarization).

          -  Clinically significant and uncontrolled major medical condition(s) that places the
             subject at an unacceptably high risk for toxicities. These include, but are not
             limited to: active infections, symptomatic pulmonary disease, inadequate pulmonary
             function, seizure disorder, psychiatric illness.

          -  Current use of more than one antihypertensive medication.

          -  For patients receiving antihypertensive medication:systolic blood pressure &lt; 120 mmHg
             and/or diastolic blood pressure &lt; 70 mmHg at screening.

          -  A known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune
             deficiency syndrome (AIDS), acute or chronic hepatitis B or hepatitis C infection, as
             determined by medical history.

          -  Major surgical procedure within 4 weeks prior to enrolment.

          -  Lactating or pregnant female.

          -  Females of childbearing potential and males not using adequate birth control.

          -  Current treatment or treatment within 4 weeks of screening with bisphosphonates.

          -  Screening serum calcium levels &lt; 2.20 mmol/L [8.8 mg/dL] (after correction for serum
             albumin

          -  History of acute pancreatitis within 12 months prior to screening

          -  Known hypoparathyroidism, pseudohypoparathyroidism, or vitamin D deficiency, or
             clinical evidence of other conditions known to associated with hypocalcemia,
             including:, hypoalbuminemia, hyperphosphatemia, hypomagnesemia

          -  Current treatment or treatment within 4 weeks of screening with drugs known to reduce
             serum calcium levels, including: bisphosphonates, antiepileptic drugs, cinacalcet,
             macrolide antibiotics (such as erythromycin, azithromycin), large doses of
             corticosteroids (&gt;20 mg/day of prednisone or equivalent), or any IV use of
             corticosteroids. In addition, long-term use (defined as ongoing use for ≥4 weeks) of
             corticosteroids within 8 weeks of screening is prohibited

          -  Any history of a venous thromboembolic event (VTE), including deep vein thrombosis
             (DVT) or pulmonary embolism (PE)

          -  Current treatment or treatment within 7 days of screening with a vitamin K antagonist,
             such as warfarin. Patients who require anticoagulation due to their central line may
             receive an alternative agent, such as low molecular weight heparin (LMWH).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toney T Ilenchuk, MS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Soricimed Biopharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230-1402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>TRPV6 Calcium channel</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

